Navigation Links
Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
Date:2/5/2008

FRANKLIN, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a specialty pharmaceuticals and diabetes management company, announced today that Patrick T. Mooney, M.D, Chairman and Chief Executive Officer, will present at the RedChip Small-Cap Investor Conference on February 7, 2008 at 3:50 pm Mountain Standard Time (5:50 pm Eastern Standard Time). The conference will be held at the Four Seasons Resort in Scottsdale, Arizona. A live video webcast of the presentation will be available on the RedChip Small-Cap Investor Conference website, http://www.visualwebcaster.com/RedChipfeb2008/. A replay of the webcast and the corresponding presentation will be available on Echo Therapeutics' website shortly following the live presentation.

About Echo Therapeutics

Echo Therapeutics is a platform-enabled, specialty pharmaceuticals and diabetes management company leveraging its expertise in transdermal science to develop and commercialize non-invasive specialty pharmaceutical products and medical devices. Echo's Symphony(TM) CTGM System is a next generation needle- free, wireless, continuous transdermal glucose monitoring (CTGM) system for diabetes home use and emerging hospital critical care markets. Symphony is designed to provide on-demand glucose data conveniently, continuously and cost-effectively. Symphony incorporates Echo's patented feedback mechanism for optimal skin permeation control and its continuous transdermal biosensor. With Symphony, Echo is focused on changing the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care settings. Echo is also marshalling the potential of its patented AzoneTS(TM) transdermal drug delivery technology to build an extensive pipeline of advanced topical reformulations of FDA-approved products in accordance with the FDA's Section 505(b)(2) guidelines. Echo has sub
'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
2. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
3. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
4. Taligen Therapeutics Secures Series B Financing
5. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
7. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
8. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
9. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
10. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 Research and ... "Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, ... report to their offering. The ... million in 2013, and is expected to grow at ... 2018. Molecular biology enzymes, kits, & reagents find applications ...
(Date:8/21/2014)... Aug. 21, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... first in class collagenase-based products marketed as XIAFLEX ... the U.S. and XIAPEX ® in the ... a randomized, double-blind Phase 2a study of CCH ... fibrosclerotic panniculopathy. The results showed that all three ...
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... Mathematic studies at the Program for Evolutionary Dynamics ... Jeffrey Epstein VI Foundation , have shown that the ... elimination. These aggressive cells are the driver mutations that drive ... of what to look for when examining tumors, comes at ... can be extracted from biopsy, it,s very difficult to know ...
Breaking Biology Technology:Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2
... 20 /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ... U.S. Patent and,Trademark office has issued a ... in preclinical development. The newly issued patent, ... composition of matter of PX-867,and pharmaceutical preparations ...
... 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ... fully integrated,biotechnology company focused on researching, developing, ... announced today,that its board of directors has ... board has authorized 3SBio to purchase up ...
... CAMBRIDGE, Mass., March 19 Genzyme Corp.,(Nasdaq: ... application,to extend the Evoltra(R) (clofarabine) product label to include ... This,application and the data on which it was based ... by Genzyme last year., In a letter to ...
Cached Biology Technology:Oncothyreon announces issuance of patent for PX-867 2Oncothyreon announces issuance of patent for PX-867 33SBio Inc. Approves Share Repurchase Program 2Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients 2Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients 3
(Date:8/21/2014)... but they are the ultimate source of all organic ... dependent on algae, too, to suck up climate-warming carbon ... bottom of the ocean. Now, by using a combination ... showing that viruses infecting those algae are driving the ... else stays essentially the same, and this has important ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- LiveScan Service Provider  Binary ... a partnership with Gabriel Health Institute, one of ... Certified Nursing Assistant preparatory schools. The agreement ... member of Binary,s LiveScan service provider,s owner/operator team; ... its service capabilities by widening the service ...
(Date:8/21/2014)... -- Nine researchers from Beth Israel Deaconess ... in "The World,s Most Influential Scientific Minds 2014," ... Thomson Reuters ScienceWatch, a web resource for science metrics ... recognized as among the most influential "are performing and ... the advancement of their science," according to a Thomson ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3
... For Immediate Release - The Scripps Research Institute has ... J. John Goodman, M.D., to Scripps Florida. The gift will ... the development of a new approach to detect and treat ... program endowment. "We are grateful to Jay and Judy ...
... Researchers have uncovered the genetic basis of remarkable broad-spectrum ... the world, is the most important pathogen affecting leafy and ... oilseed rape. They have tested resistant plants against a range ... the world and so far, no strain has been able ...
... CINCINNATIA new international population study, led by the University ... human developmental effects of environmental exposure to the complex ... UC epidemiologist Aimin Chen, MD, PhD, says research on ... in e-waste is urgently needed in order to avoid ...
Cached Biology News:New disease-resistant food crops in prospect 2Human health effects of 'e-waste' focus of international research study 2
Mouse Amphiregulin MAb (Clone 206220)...
Anti-Digoxigenin-AP, Fab fragments; from sheep...
The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
Biology Products: